A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
April 03, 2023 08:13 ET
|
HCW Biologics, Inc
HCW Biologics Published a Pivotal Scientific Paper in Aging Cell Subcutaneous Administration of HCW9218 Systemically Reduces Senescent Cells and Alleviates Senescence-Associated Secretory Phenotype...
HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
March 28, 2023 16:25 ET
|
HCW Biologics, Inc
MIRAMAR, Fla., March 28, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Biologics Enters CRADA with National Cancer Institute
December 08, 2022 07:55 ET
|
HCW Biologics, Inc
MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
December 07, 2022 07:30 ET
|
HCW Biologics, Inc
Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical...
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting
November 08, 2022 07:00 ET
|
HCW Biologics, Inc
Presentation includes data on safety and dosage escalationand immune system reaction to HCW9218 No incidence of mucosal bleeding resulting from the HCW9218 TGF-β trap HCW9218 is one of the lead...
HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights
November 07, 2022 16:45 ET
|
HCW Biologics, Inc
MIRAMAR, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights
August 12, 2022 07:00 ET
|
HCW Biologics, Inc
MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
U.S. Patent Issued to HCW Biologics for Foundational Platform Technology
August 03, 2022 07:15 ET
|
HCW Biologics, Inc
MIRAMAR, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022
May 23, 2022 07:30 ET
|
HCW Biologics, Inc
MIRAMAR, Fla., May 23, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 13, 2022 07:15 ET
|
HCW Biologics, Inc
MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel...